Not independent
Tenure on this board
3.5 yrs
Meeting calendar
BLFS · Annual meeting · Wednesday, August 20, 2025
Biolife Solutions Inc
7 nominees · 3 ballot items.
The proxy statement includes three proposals: (1) election of seven director nominees to the Board; (2) advisory approval of executive compensation for named officers; and (3) ratification of Grant Thornton LLP as the company’s independent registered public accounting firm for 2025.
Market cap
$1.4B
1Y TSR
+20.5%
Board grade
C-
Record date
Jun 23, 2025
Filing
DEF 14A
Meeting concluded · Aug 20, 2025
Follow how the vote landed and what changed on Biolife Solutions Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of Directors
ManagementBoard: FORTo elect the seven (7) director nominees named in the attached proxy statement to serve until his/her successor is duly elected and qualified, unless he/she resigns, is removed or otherwise is disqualified from serving as a director of the Company;
- 2
Approval on an Advisory Basis of the Compensation of Named Executive Officers
ManagementBoard: FORTo approve on a non-binding, advisory basis the compensation of our named executive officers;
- 3
Ratification of the Appointment by the Audit Committee of Grant Thornton LLP as the Company’s Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2025
ManagementBoard: FORTo ratify the appointment by our Audit Committee of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025;
Director elections
Nominees on the ballot7
Independent
Tenure on this board
1.3 yrs
Independent
Tenure on this board
5.3 yrs
Independent
Tenure on this board
5.3 yrs
Independent
Tenure on this board
4.8 yrs
Independent
Tenure on this board
1.5 yrs
Also a director at
908 Devices Inc (MASS)
Independent
Tenure on this board
3.8 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | T. Rowe Price Investment Management, Inc. | 13.3% | 6,506,346 | $124M |
| 2 | Casdin Capital, LLC | 12.2% | 5,957,165 | $114M |
| 3 | BlackRock, Inc. | 8.9% | 4,324,505 | $83M |
| 4 | Invesco Ltd. | 4.5% | 2,213,396 | $42M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 3.9% | 1,917,708 | $37M |
| 6 | STATE STREET CORP | 3.2% | 1,577,076 | $30M |
| 7 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 2.4% | 1,189,874 | $23M |
| 8 | BlackRock, Inc. | 2.3% | 1,133,711 | $22M |
| 9 | FRED ALGER MANAGEMENT, LLC | 2.2% | 1,079,935 | $21M |
| 10 | FMR LLC | 2.1% | 1,001,738 | $19M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Biolife Solutions Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.9B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$2.0B
Esperion Therapeutics IncESPR
Special meeting·Jul 8, 2026·$814M
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$734M
Achieve Life Sciences IncACHV
Annual meeting·Jul 2, 2026·$670M
Reference
Frequently asked questions
- When is the Biolife Solutions Inc 2025 annual meeting?
- Biolife Solutions Inc (BLFS) holds its 2025 annual shareholder meeting on Wednesday, August 20, 2025.
- What is the record date for the Biolife Solutions Inc 2025 meeting?
- The record date for the Biolife Solutions Inc 2025 meeting is Monday, June 23, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Biolife Solutions Inc's 2025 meeting?
- The board is presenting 7 director nominees at the Biolife Solutions Inc 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Biolife Solutions Inc 2025 meeting?
- Shareholders will vote on 3 proposals at the Biolife Solutions Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.